Ashley Ivor Simon Morris
Keine laufenden Positionen mehr
Karriereverlauf von Ashley Ivor Simon Morris
Ehemalige bekannte Positionen von Ashley Ivor Simon Morris
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SCIGEN LIMITED | Direktor/Vorstandsmitglied | 14.02.2017 | 08.09.2017 |
| Vorstandsvorsitzender | 09.02.2017 | 08.09.2017 | |
| MERCK SHARP DOHME PHARMA TBK PT | Corporate Officer/Principal | 01.01.2004 | 01.01.2009 |
Ausbildung von Ashley Ivor Simon Morris
| The University of Nottingham | Undergraduate Degree |
Statistik
International
| Singapur | 2 |
| Vereinigtes Königreich | 2 |
| Indonesien | 2 |
Operativ
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MERCK SHARP DOHME PHARMA TBK PT | Health Technology |
| Private Unternehmen | 1 |
|---|---|
SciGen Pte Ltd.
 SciGen Pte Ltd. Pharmaceuticals: MajorHealth Technology SciGen Pte Ltd. engages in the development, manufacturing, and marketing of biopharmaceutical products. It operates through following segments: Singapore, Australia, Korea, Thailand, Philippines, China, and Others. The Singapore segment comprises of corporate office functions, sales, and marketing. The Australia, Korea, Thailand, and Philippines segments deal with sales and marketing activities. The China segment is involved in regulatory activities. The Others segment covers operations on in Indonesia, Pakistan, Vietnam, Hong Kong, Myanmar, Malaysia, and profit sharing income on sale of insulin. The firm's products include SciLin, SciTropin A, SciLocyte, SciTrace 5 Injection, and Heri Injection. The company was founded by Saul Akerib Mashaal in 1988 and is headquartered in Singapore. | Health Technology |
